Biondvax Pharmaceuticals Ltd. (BVXV)

Trade BVXV now with
7/1/2020 6:03:06 AM BiondVax: Last Of 12,400 Participants Completes Final Visit In M-001 Universal Flu Vaccine Pivotal Phase 3 Trial
6/12/2020 8:07:37 AM BiondVax Pharma FY Loss Per Share NIS 0.33 Vs Loss NIS 0.34 Last Year
6/10/2020 7:07:18 AM BiondVax Pharma Reports Completion Of CSR Of Phase 2 Clinical Trial Of M-001 Universal Influenza Vaccine Candidate
5/20/2020 6:35:02 AM BiondVax Announces Receipt Of Proceeds Of $4.2 Mln Since January 1, 2020 Through Exercises Of BiondVax Warrants
3/19/2020 7:19:48 AM BiondVax's CEO Says Coronavirus Pandemic Has Not Significantly Impacted Phase 3 Clinical Trial
11/18/2019 7:21:18 AM BiondVax Pharma Complets Enrollment Of 12,463 Participants Complete In Pivotal Phase 3 Universal Flu Vaccine Trial
8/28/2019 7:49:29 AM BiondVax Pharma Names Mark Germain Chairman, Effective Sept 30
7/8/2019 5:48:48 AM BiondVax Enrolls First Participants In Second Cohort Of Pivotal, Clinical Efficacy, Phase 3 Trial Of M-001
6/18/2019 6:36:26 AM BiondVax Pharma Says Patent Covering Manufacturing Process Of M-001 Universal Flu Vaccine Allowed In USA And Japan
6/10/2019 8:24:22 AM BiondVax Announces Rights Offering In Support Of Clinical Efficacy Phase 3 Trial Of The M-001 Universal Flu Vaccine
5/30/2019 7:12:57 AM BiondVax Pharma Q1 EPS NIS 0.002 Vs Loss NIS 0.05 Last Year
5/13/2019 7:04:00 AM BiondVax To Provide Update Of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial At MIXiii-BIOMED Conference
4/15/2019 7:58:17 AM Australia Accepts BiondVax Universal Flu Vaccine Patent Application
10/24/2018 7:13:40 AM BiondVax: Universal Flu Vaccine Phase 3 Trial Completes First Season's Enrollment Of 4,098 Participants
8/22/2018 7:04:01 AM BiondVax Pharma Q2 Loss Per Share NIS 0.07 Vs Loss NIS 0.10 Last Year
6/28/2018 7:06:08 AM BiondVax Appoints Mark Germain As Vice-Chairman Of Its Board
1/2/2018 9:05:58 AM BiondVax: Universal Flu Vaccine Patent Granted In India